Co-Diagnostics shares soar as its technology is used in Stanford cancer study

The aim of the Stanford study is to find better ways to detect genetic mutations which surface in lung cancer

Cancer headline in a newspaper
Co-Diagnostics shares are up sharply in pre-market trade

Investors sent shares in Co-Diagnostics Inc. (NASDAQ: CODX) flying in pre-market trade on the news that its CoPrimer technology will be used in a Stanford University research project.

The point of the study, which is being conducted by the Wang Group at Stanford, is to find better ways to detect genetic mutations in the epidermal growth factor receptor gene that surface in lung cancer.

Co-Diagnostics’ CoPrimer technology is being used by the scientists at Stanford to improve their detection methods of the mutations which cause cancer. The results of the Stanford study will be published later this year.

In response to the news, Co-Diagnostics shares jumped 12.4% to US$2.90 in pre-market trade.

“Heightened specificity and allowing for a massive reduction in false positives, are [two] of the most valuable benefits of this technology, making it ideal for cancer detection and liquid biopsy applications,” Dwight Egan, chief executive of Co-Diagnostics, said.

Based in Utah, Co-Diagnostics is a company which develops diagnostic equipment used to detect and analyze DNA and RNA.


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...



Arizona Silver Exploration Chairman Mike Stark excited about outlook for 2019

Arizona Silver Exploration (CVE:AZS) Chairman Mike Stark sat down with Steve Darling from Proactive Investors Vancouver to talk about his Chairman's letter sent out to shareholders. In it, Stark talks about the positive past year and some exciting developments for 2019. The full letter can be...

on 28/2/19

2 min read